Molecular Partners and Orano Med Expand Partnership for Cancer Therapy Development
Molecular Partners has outlined its clinical expansion plans and strengthened its strategic focus on radiopharma for 2025 at the 43rd Annual J.P. Morgan Healthcare Conference. A significant part of this plan includes the Radio-DARPin MP0712 against DLL3, developed in collaboration with Orano Med, which is set to enter its first-in-human study in 2025. Additionally, Mesothelin has been named as the second target in the Radio-DARPin pipeline, with a program to be co-developed with Orano Med.
The expanded partnership between Molecular Partners and Orano Med is aimed at fueling a broad and innovative pipeline of 212Pb-Radio-DARPin candidates, increasing the total number of programs up to ten. This collaboration highlights the commitment of both companies to advancing cancer therapy through targeted alpha radio-therapies, leveraging their combined expertise and resources to bring innovative treatments to patients.